The use of monoclonal antibodies (mAb) has been accepted as an effective cure for the treatment of cancer and autoimmune diseases. Today antibodies dominate the biopharmaceutical market and their development and production using hybridoma cells is widely established. Rising time and cost pressures in combination with the demand for higher throughput make the development of therapeutic antibodies challenging.
Many factors have to be taken into account and alternative solutions are evaluated to battle challenges like sample protection, efficiency, and reproducibility. In addition, optimized ergonomics can reduce hands-on time, protect lab staff from work-associated injuries and improve overall performance.
The mAb drug discovery process includes several centrifugation steps with individual requirements on the used device. Eppendorf solutions of centrifuges, rotors and vessel adapters are based on protocol evaluation and customer interviews within mAb drug discovery community.
Learn more about Eppendorf’s centrifuge solutions for hit to lead discovery, lead optimization, and candidate validation within the mAb drug discovery workflow (see table below).
